Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Chronic, Non-Malignant Pain

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Chronic, Non-Malignant Pain

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methylnaltrexone bromide (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Sponsors Bausch Health Companies; Salix Pharmaceuticals
  • Most Recent Events

    • 31 Mar 2021 Results of post hoc pooled analysis of (study 302, NCT00402038; study 3200K1-4000, NCT00672477; study 3200K1-3356, NCT00529087 and study 3201, NCT01186770) assessing efficacy and safety of methylnaltrexone, including the effectiveness of opioid treatment, in older adults receiving methylnaltrexone for opioid-induced constipation (OIC), published in the Drugs and Aging.
    • 05 Sep 2017 According to Salix Pharmaceuticals media release, data from this trial will be presented at PAINWeek 2017.
    • 20 May 2017 Results presented at the 36th Annual Scientific Meeting of the American Pain Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top